|
Human Protein Atlas
immunohistochemical staining data of stat3 protein ![]() Immunohistochemical Staining Data Of Stat3 Protein, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/immunohistochemical+staining+data/immunohistochemical+staining+data+of+stat3+protein/pmc10505358-86-5-16 Average 90 stars, based on 1 article reviews
immunohistochemical staining data of stat3 protein - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Human Protein Atlas
immunohistochemical staining data for ptov1 ![]() Immunohistochemical Staining Data For Ptov1, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/immunohistochemical+staining+data/immunohistochemical+staining+data+for+ptov1/pmc11369455-90-5-19 Average 90 stars, based on 1 article reviews
immunohistochemical staining data for ptov1 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Human Protein Atlas
immunohistochemical staining data for ascl1 ![]() Immunohistochemical Staining Data For Ascl1, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/immunohistochemical+staining+data/immunohistochemical+staining+data+for+ascl1/pmc11830715-44-5-17 Average 90 stars, based on 1 article reviews
immunohistochemical staining data for ascl1 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Human Protein Atlas
immunohistochemical (ihc) staining data for krt7 ![]() Immunohistochemical (Ihc) Staining Data For Krt7, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/immunohistochemical+staining+data/immunohistochemical++ihc++staining+data+for+krt7/pmc11865440-130-6-9 Average 90 stars, based on 1 article reviews
immunohistochemical (ihc) staining data for krt7 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Human Protein Atlas
immunohistochemical staining data of oxphos-related proteins and mrps ![]() Immunohistochemical Staining Data Of Oxphos Related Proteins And Mrps, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/immunohistochemical+staining+data/immunohistochemical+staining+data+of+oxphos+related+proteins+and+mrps/10__1097_slash_md__0000000000000273-36-13-17 Average 90 stars, based on 1 article reviews
immunohistochemical staining data of oxphos-related proteins and mrps - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Human Protein Atlas
immunohistochemical staining data for spata2 ![]() Immunohistochemical Staining Data For Spata2, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/immunohistochemical+staining+data/immunohistochemical+staining+data+for+spata2/pm40069269-268-7-10 Average 90 stars, based on 1 article reviews
immunohistochemical staining data for spata2 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Human Protein Atlas
immunohistochemical staining data of angptl4-related proteins ![]() Immunohistochemical Staining Data Of Angptl4 Related Proteins, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/immunohistochemical+staining+data/immunohistochemical+staining+data+of+angptl4+related+proteins/pmc09247875-90-10-19 Average 90 stars, based on 1 article reviews
immunohistochemical staining data of angptl4-related proteins - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Human Protein Atlas
immunohistochemical staining data for dtx2 ![]() Immunohistochemical Staining Data For Dtx2, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/immunohistochemical+staining+data/immunohistochemical+staining+data+for+dtx2/pm39366066-67-4-9 Average 90 stars, based on 1 article reviews
immunohistochemical staining data for dtx2 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Human Protein Atlas
immunohistochemical staining data of trim32 ![]() Immunohistochemical Staining Data Of Trim32, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/immunohistochemical+staining+data/immunohistochemical+staining+data+of+trim32/pm30378152-78-9-20 Average 90 stars, based on 1 article reviews
immunohistochemical staining data of trim32 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Open Medicine
Article Title: A pan-cancer analysis of STAT3 expression and genetic alterations in human tumors
doi: 10.1515/med-2023-0792
Figure Lengend Snippet: Prognostic survival analysis. (a)−(c) K−M survival analysis showed that the OS of LGG, TGCT, and SKCM in STAT3 high expression group was significantly different. (d) COX regression analysis showed that the OS of LGG and SKCM were significantly correlated with the expression of STAT3. (e)−(i) PFS of LGG, HNSC, SKCM, PRAD, and COAD were significantly different. (j) COX regression analysis showed that only LGG had significant difference in PFS and STAT3 expression.
Article Snippet: The immunohistochemical staining data of
Techniques: Expressing
Journal: Open Medicine
Article Title: A pan-cancer analysis of STAT3 expression and genetic alterations in human tumors
doi: 10.1515/med-2023-0792
Figure Lengend Snippet: Verification of CGGA: (a) result of K−M survival analysis, (b) results of univariate analysis, (c) results of multivariate analysis, (d) ROC curve, (e) immunohistochemical staining showed that STAT3 was negative staining in normal tissue, and (f) immunohistochemical staining showed that STAT3 was medium positive in LGG.
Article Snippet: The immunohistochemical staining data of
Techniques: Immunohistochemical staining, Staining, Negative Staining
Journal: Open Medicine
Article Title: A pan-cancer analysis of STAT3 expression and genetic alterations in human tumors
doi: 10.1515/med-2023-0792
Figure Lengend Snippet: Results of immune correlation analysis: (a) immune score of LGG by IME analysis, (b) matrix score of LGG by IME analysis, (c)−(k) results of immune cell infiltration, and (l) correlations between immune checkpoints and STAT3 expression.
Article Snippet: The immunohistochemical staining data of
Techniques: Expressing
Journal: Open Medicine
Article Title: A pan-cancer analysis of STAT3 expression and genetic alterations in human tumors
doi: 10.1515/med-2023-0792
Figure Lengend Snippet: Genetic alteration analysis: (a) radar map shows the correlation between STAT3 expression and TMB, (b) radar map shows the correlation between STAT3 expression and MSI, (c) alteration frequency of ADAM12 in different tumors, (d) mutation lollipop chart provides information on the mutation sites and mutation types, (e) 3D structure of the STAT3 protein and the Y640F site, (f) an overview of the types of mutations observed that are curated by COSMIC, (g) protein sequence features of STAT3 protein curated by COSMIC, and (h) 3D structure and missense mutation frequency of STAT3 protein that are curated by COSMIC (the redder the color, the higher the missense mutation frequency).
Article Snippet: The immunohistochemical staining data of
Techniques: Expressing, Mutagenesis, Sequencing
Journal: Heliyon
Article Title: PTOV1 facilitates colorectal cancer cell proliferation through activating AKT1 signaling pathway
doi: 10.1016/j.heliyon.2024.e36017
Figure Lengend Snippet: PTOV1 expression is negatively regulated by the DNA methylation of PTOV1 promoter in CRC. (A) Methylation of the PTOV1 promoter is lower in CRC compared with normal tissue in TCGA-COAD datasets collected by UALCAN. (B) MEXPRESS tool analysis for the relationship between the degree of PTOV1 promoter methylation and its expression level in COAD. (C) The CpG methylation level of PTOV1 in normal and primary tumor tissue among cancer types in COAD (n = 38 and n = 309 respectively). (D) The correlation between methylation of the two CpG sites and PTOV1 expression, respectively (n = 347). (E) The genomic coordinates of PTOV1 promoter region CpG island and MSP primer locations. (F) PTOV1 promoter methylation levels in SW480 (n = 5 each group) and HCT116 (n = 6 each group) with or without 5‐aza‐dC treatment by conducted MSP. (G–H) The protein (n = 3) and mRNA (n = 5) level of PTOV1 in SW480 and HCT116 with or without 5‐aza‐dC treatment. Note: *P < 0.05, **P < 0.01. U: unmethylated; M: methylated.
Article Snippet: Furthermore, immunohistochemical staining data for
Techniques: Expressing, DNA Methylation Assay, Methylation, CpG Methylation Assay
Journal: Heliyon
Article Title: PTOV1 facilitates colorectal cancer cell proliferation through activating AKT1 signaling pathway
doi: 10.1016/j.heliyon.2024.e36017
Figure Lengend Snippet: The High PTOV1 Expression is Associated with Poor Survival in CRC Patients. (A) High or low expression of PTOV1 in different human cancer tissues compared with normal tissues using the TIMER database. (B) PTOV1 mRNA expression levels in CRC and normal tissue samples analyzed in the TCGA databases. (C–F) The expression levels of PTOV1 in colorectal cancer and normal tissue samples in GSE110223, GSE20842, GSE41258 and GSE23878 datasets. (G) PTOV1 protein was significantly upregulated from CPTAC samples. (H) The protein expression of PTOV1 in CRC tissues and normal tissues from the Human Protein Atlas. (I) IHC analysis PTOV1 expression in mouse tissues (each group: n = 6). (J) Survival curves of the CRC patients (n(high) = 1524, n(low) = 565). (K) Forest plot illustrated the results of multivariate Cox regression analyses. Note: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Scare bar = 100 μm.
Article Snippet: Furthermore, immunohistochemical staining data for
Techniques: Expressing
Journal: Heliyon
Article Title: PTOV1 facilitates colorectal cancer cell proliferation through activating AKT1 signaling pathway
doi: 10.1016/j.heliyon.2024.e36017
Figure Lengend Snippet: Correlation between PTOV1 expression and clinicopathologic characteristics of CRC patients.
Article Snippet: Furthermore, immunohistochemical staining data for
Techniques: Expressing
Journal: Heliyon
Article Title: PTOV1 facilitates colorectal cancer cell proliferation through activating AKT1 signaling pathway
doi: 10.1016/j.heliyon.2024.e36017
Figure Lengend Snippet: Univariate and multivariate Cox regression analysis of prognostic factors in CRC patients for overall survival.
Article Snippet: Furthermore, immunohistochemical staining data for
Techniques: Expressing
Journal: Heliyon
Article Title: PTOV1 facilitates colorectal cancer cell proliferation through activating AKT1 signaling pathway
doi: 10.1016/j.heliyon.2024.e36017
Figure Lengend Snippet: The correlation between PTOV1 expression and lymphocyte subtypes.
Article Snippet: Furthermore, immunohistochemical staining data for
Techniques: Expressing, Derivative Assay
Journal: Heliyon
Article Title: PTOV1 facilitates colorectal cancer cell proliferation through activating AKT1 signaling pathway
doi: 10.1016/j.heliyon.2024.e36017
Figure Lengend Snippet: The relationship between PTOV1 and immune in colorectal cancer. (A) Different proportions of sorts of immune cells in high- and low-PTOV1 groups in CRC specimens by CIBERSORTx methods. (B) The relationship between PTOV1 expression and the abundance of immune cells in CRC. (C–F) The relationship between PTOV1 expression and the abundance of TILs, immunoinhibitor, immunostimulators and MHC molecules in CRC. Note: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Article Snippet: Furthermore, immunohistochemical staining data for
Techniques: Expressing
Journal: Heliyon
Article Title: PTOV1 facilitates colorectal cancer cell proliferation through activating AKT1 signaling pathway
doi: 10.1016/j.heliyon.2024.e36017
Figure Lengend Snippet: PTOV1 Promotes CRC Cell Proliferation Ability. (A–B) The baseline protein and mRNA level of PTOV1 in NCM460 and CRC cells (n = 3 and n = 5 each group respectively). (C–D) The protein and mRNA expression level of PTOV1 in SW480 (n = 4 and n = 5 each group respectively) and HCT116 (n = 4 each group) cells transfected PTOV1 specific siRNA (n = 4 and n = 5 each group respectively). (E–F) The protein and mRNA expression level of PTOV1 in SW480 (n = 4 and n = 3 each group respectively) and HCT116 (n = 4 each group) cells transfected PTOV1 overexpressed plasmid. (G) Cell proliferation after PTOV1 over-expression (n = 6 each group) or suppressed by siRNA (n = 6 each group) in SW480 cells was determined by CCK-8 assay. (n = 6). (H) Cell proliferation after PTOV1 over-expression (n = 5 each group) or suppressed by siRNA (n = 5 each group) in HCT116 cells was determined by CCK-8 assay. (n = 6). (I) Colony formation assays for SW480 cells showed PTOV1 knockdown (n = 6 each group) decreased cell viability and overexpression of PTOV1 (n = 6 each group) increased cell viability. (J) Colony formation assays for HCT116 cells showed PTOV1 knockdown (n = 3 each group) decreased cell viability and overexpression of PTOV1 (n = 3 each group) increased cell viability. Note: *P < 0.05, #P < 0.05, &P < 0.05; Data are presented as means ± SD.
Article Snippet: Furthermore, immunohistochemical staining data for
Techniques: Expressing, Transfection, Plasmid Preparation, Over Expression, CCK-8 Assay, Knockdown
Journal: Heliyon
Article Title: PTOV1 facilitates colorectal cancer cell proliferation through activating AKT1 signaling pathway
doi: 10.1016/j.heliyon.2024.e36017
Figure Lengend Snippet: Knockdown of PTOV1 induces cell cycle arrest and inhibit cell migration ability. (A–B) Cell cycle analysis with flow cytometry at 48 h after transfection. The bar chart represents the percentage of cells in G0/G1, S, or G2/M phase, as indicated. (C) The migration ability of CRC cells was measured by transwell assay (n = 3). Note: *P < 0.05, #P < 0.05, &P < 0.05; Data are presented as means ± SD.
Article Snippet: Furthermore, immunohistochemical staining data for
Techniques: Knockdown, Migration, Cell Cycle Assay, Flow Cytometry, Transfection, Transwell Assay
Journal: Heliyon
Article Title: PTOV1 facilitates colorectal cancer cell proliferation through activating AKT1 signaling pathway
doi: 10.1016/j.heliyon.2024.e36017
Figure Lengend Snippet: Analysis of the biological functions and signaling pathways of PTOV1 in CRC A volcanic map of gene changes associated with PTOV1 expression in CRC. (B–C) Heat maps of the top 30 genes of PTOV1 positively and negatively associated in CRC. (D) GO terms in the biological process (BP), cellular compartment (CC), molecular function (MF) and KEGG pathways. (E) GSEA was performed using the high- and low-PTOV1 expression groups stratified by the median PTOV1 expression in TCGA-COADREAD. GSEA reveal significant differences (NOM P < 0.05, FDR <0.25) in enrichment of MSigDB Collection. (F) qRT-PCR analysis for expression of P21, P27, cyclin D1, and CDK2 in SW480 cells (n = 5). (G–H) P27, P21 and AKT1 protein were measured by Western blot in SW480 (n = 3) and HCT116 (n = 3) cells. Note: *P < 0.05, #P < 0.05; Data are presented as means ± SD.
Article Snippet: Furthermore, immunohistochemical staining data for
Techniques: Protein-Protein interactions, Expressing, Quantitative RT-PCR, Western Blot
Journal: Heliyon
Article Title: PTOV1 facilitates colorectal cancer cell proliferation through activating AKT1 signaling pathway
doi: 10.1016/j.heliyon.2024.e36017
Figure Lengend Snippet: POTV1 promotes CRC cells proliferation via regulating AKT signaling pathway. (A) AKT1, P21 and P27 expression within PTOV1-overexpressed SW480 cell line and normal control with or without incubation with MK2206 (n = 3). (B) qRT-PCR analysis of P21 and P27 in PTOV1-overexpressed SW480 cells and normal control with or without incubation with MK2206. (C) CCK8 and colony formation assay in PTOV1-overexpressed SW480 cells and normal control with or without exposure to MK2206 (n = 3). (E) Graphical abstract. high level of PTOV1 mediated by hypomethylated in promoter region promotes the proliferation of CRC cells through activating of AKT1. Note: *P < 0.05, #P < 0.05; Data are presented as means ± SD; . Resulting heat map visualizing the correlation matrix of diverse tumor-infiltrating immune cells subpopulations. Each tile indicates coefficients calculated by Pearson's correlation test. Note: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Article Snippet: Furthermore, immunohistochemical staining data for
Techniques: Expressing, Control, Incubation, Quantitative RT-PCR, Colony Assay
Journal: Frontiers in Immunology
Article Title: An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis
doi: 10.3389/fimmu.2025.1546794
Figure Lengend Snippet: ASCL1 is highly expressed in BC and correlates with poor prognosis. (A) Comparative analysis of ASCL1 mRNA expression across pan-cancers, including BC, and normal tissues based on data from the TCGA and GTEx databases. (B, C) ASCL1 mRNA expression comparison between BC and normal tissues using data from (B) the combined TCGA and GTEx databases, and (C) the TCGA database alone. (D) ASCL1 mRNA expression in paired BC and adjacent normal tissues from the TCGA database. (E) Immunohistochemical staining of ASCL1 in normal breast tissue from the HPA database. (F) Immunohistochemical staining of ASCL1 in BC tissues. (G) Protein expression levels of ASCL1 in normal breast epithelial cells and BC cell lines. (H, I) Prognostic impact of ASCL1 expression on (H) RFS, (I) OS in patients with BC. (* P < 0.05; ** P < 0.01; *** P < 0.001).
Article Snippet: Additionally, immunohistochemical staining data for
Techniques: Expressing, Comparison, Immunohistochemical staining, Staining
Journal: Frontiers in Immunology
Article Title: An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis
doi: 10.3389/fimmu.2025.1546794
Figure Lengend Snippet: Genetic alterations of ASCL1 in BC and their relationship to mutations in other key genes. (A, B) Oncoprint representation of ASCL1 genetic alterations in (A) primary BC and (B) metastatic BC, based on data from the cBioPortal database. (C) Diagram showing ASCL1 mutations across protein domains in metastatic BC, derived from cBioPortal data. (D, E) Types of (D) ASCL1 mutations and (E) specific substitution mutation of ASCL1 in BC from the COSMIC database. (F) Mutation landscape of key genes stratified by high and low ASCL1 expression in BC.
Article Snippet: Additionally, immunohistochemical staining data for
Techniques: Derivative Assay, Mutagenesis, Expressing
Journal: Frontiers in Immunology
Article Title: An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis
doi: 10.3389/fimmu.2025.1546794
Figure Lengend Snippet: Correlation between ASCL1 expression and immunomodulatory factors in pan-cancer analysis. (A) Pearson and (B) Spearman correlation analyses between ASCL1 and immunomodulatory factors from the TCGA database.
Article Snippet: Additionally, immunohistochemical staining data for
Techniques: Expressing
Journal: Frontiers in Immunology
Article Title: An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis
doi: 10.3389/fimmu.2025.1546794
Figure Lengend Snippet: Association of ASCL1 expression with tumor immunity and chemotherapy response in BC. (A-F) Correlations between ASCL1 expression and immune cell infiltration, using various methods: (A) QUANTISEQ, (B) TIMER, (C) EPIC, (D) MCP-COUNTER, (E) CIBERSORT, and (F) XCELL. (G) Correlation between ASCL1 expression and immune activity score in BC. (H-K) Comparison of IC50 values for common chemotherapeutic drugs between high and low ASCL1 expression groups in BC: (H) docetaxel, (I) paclitaxel, (J) cisplatin, and (K) doxorubicin. (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001), ns, not significant.
Article Snippet: Additionally, immunohistochemical staining data for
Techniques: Expressing, Activity Assay, Comparison
Journal: Frontiers in Immunology
Article Title: An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis
doi: 10.3389/fimmu.2025.1546794
Figure Lengend Snippet: ASCL1 promotes BC cell progression. (A, B) Assessment of ASCL1 overexpression efficiency through (A) qRT-PCR and (B) Western blot analysis. (C, D) (C) Colony formation assay and (D) CCK-8 assay showing that ASCL1 overexpression enhances the proliferation of MCF-7 and MDA-MB-231 cells. (E, F) Wound healing assay demonstrating enhanced migration of (E) MCF-7 and (F) MDA-MB-231 cells with ASCL1 overexpression (scale bar = 500μm). (G, H) Histogram of percentage of wound migration area for (G) MCF-7 and (H) MDA-MB-231 cells. (I, J) Transwell assay revealing that ASCL1 overexpression promotes migration and invasion of (I) MCF-7 and (J) MDA-MB-231 cells (scale bar = 200μm). (K, L) Histogram of the results of transwell assay on (K) MCF-7 and (L) MDA-MB-231 cells. (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001).
Article Snippet: Additionally, immunohistochemical staining data for
Techniques: Over Expression, Quantitative RT-PCR, Western Blot, Colony Assay, CCK-8 Assay, Wound Healing Assay, Migration, Transwell Assay
Journal: Frontiers in Immunology
Article Title: An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis
doi: 10.3389/fimmu.2025.1546794
Figure Lengend Snippet: Knockdown of ASCL1 inhibits BC progression in vitro . (A, B) Evaluation of ASCL1 knockdown efficiency following plasmid transfection using (A) qRT-PCR and (B) Western blot analysis. (C) CCK-8 assay indicates that ASCL1 knockdown suppresses BC cell proliferation in vitro . (D, E) Wound healing assay showing that ASCL1 knockdown inhibits migration in (D) MCF-7 and (E) MDA-MB-231 cells (scale bar = 500μm). (F, G) Histogram of percentage of wound migration area for (F) MCF-7 and (G) MDA-MB-231 cells. (H, I) Transwell assay demonstrating that ASCL1 knockdown suppresses migration and invasion in (H) MCF-7 and (I) MDA-MB-231 cells (scale bar = 200μm). (J, K) Histogram of the results of transwell assay on (J) MCF-7 and (K) MDA-MB-231 cells. (L) ASCL1 knockdown inhibits the EMT process in BC. (M, N) ASCL1 knockdown enhances paclitaxel sensitivity in (M) MCF-7 and (N) MDA-MB-231 cells. (O) Reduction in ABCG2 expression following ASCL1 knockdown in BC cells. (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001).
Article Snippet: Additionally, immunohistochemical staining data for
Techniques: Knockdown, In Vitro, Plasmid Preparation, Transfection, Quantitative RT-PCR, Western Blot, CCK-8 Assay, Wound Healing Assay, Migration, Transwell Assay, Expressing
Journal: Frontiers in Immunology
Article Title: An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis
doi: 10.3389/fimmu.2025.1546794
Figure Lengend Snippet: ASCL1 knockdown activates ferroptosis in BC cells. (A) GSEA indicates an association between ASCL1 and ferroptosis in BC. (B) Increased MDA levels due to ASCL1 knockdown. (C) Decreased GSH levels in BC cells with ASCL1 knockdown. (D) Reduction in the GSH/GSSG ratio following ASCL1 knockdown. (E, F) Elevated ROS levels following ASCL1 knockdown in BC cells (scale bar = 500μm). (G, H) TEM showing changes in mitochondrial morphology characteristic of ferroptosis after ASCL1 downregulation in (G) MCF-7 and (H) MDA-MB-231(scale bar = 2μm and 500 nm). (I, J) ASCL1 knockdown enhances paclitaxel sensitivity associated with ferroptosis in (I) MCF-7 and (J) MDA-MB-231 cells (Erastin: 5 μM, ferrostatin-1: 2 μM, paclitaxel (MCF-7): 0.01 mg/L, paclitaxel (MDA-MB-231): 1 mg/L). (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001), ns, not significant.
Article Snippet: Additionally, immunohistochemical staining data for
Techniques: Knockdown
Journal: Frontiers in Immunology
Article Title: An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis
doi: 10.3389/fimmu.2025.1546794
Figure Lengend Snippet: Inhibition of ASCL1 activates ferroptosis via the CREB1/GPX4 axis. (A) KEGG analysis indicates an association between ASCL1 and the cAMP pathway. (B) Protein docking map and binding site of ASCL1 to CREB1. (C) Immunofluorescence assay illustrates co-localization of ASCL1 with CREB1. (D) Co-IP assay indicates that ASCL1 binds to CREB1 in BC. (E) ASCL1 knockdown inhibits the CREB1/GPX4 pathway in BC cells. (* P < 0.05; ** P < 0.01; *** P < 0.001).
Article Snippet: Additionally, immunohistochemical staining data for
Techniques: Inhibition, Binding Assay, Immunofluorescence, Co-Immunoprecipitation Assay, Knockdown
Journal: Frontiers in Immunology
Article Title: An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis
doi: 10.3389/fimmu.2025.1546794
Figure Lengend Snippet: ASCL1 knockdown enhances BC sensitivity to paclitaxel in vivo . (A) Schematic representation of the in vivo experimental design. (B) Photograph of tumors collected at the end of the experiment. (C) Tumor volume progression over time in both groups during the experiment. (D) Comparison of tumor weights between the two groups at the conclusion of the experiment. (E) ASCL1 knockdown inhibits the CREB1/GPX4 pathway in vivo . (*** P < 0.001; **** P < 0.0001).
Article Snippet: Additionally, immunohistochemical staining data for
Techniques: Knockdown, In Vivo, Comparison
Journal: Scientific Reports
Article Title: KRT7 promotes pancreatic cancer metastasis by remodeling the extracellular matrix niche through FGF2-fibroblast crosstalk
doi: 10.1038/s41598-024-84129-1
Figure Lengend Snippet: Identification of KRT7 as a differentially expressed gene. ( A ) Volcano plot (|log 2 FC| > 1, P value < 0.05) of the GSE71729 data. ( B ) Volcano plot (|log 2 FC| > 1, P value < 0.05) of the TCGA-PDAC data. ( C ) Volcano plot (|log 2 FC| > 1, P value < 0.05) of the GSE151580 data. ( D ) Venn diagram of the overlapping DEGs among the GSE71729, TCGA and GSE151580 dataset. ( E ) Differential mountain maps of PDAC samples according to proteomics. ( F ) Venn diagram of KRT7 overexpression data. ( G ) OS probability curve of patients stratified by KRT7 expression according to data from the KM plotter database. ( H ) OS and DFS curves of patients stratified by the median KRT7 expression level according to data from the GEPIA2 database. ( I ) OS and DFS curves of patients stratified by KRT7 expression quartiles according to data from the GEPIA2 database. ( J ) The expression of KRT7 in tumor and normal tissues according to data from the GEPIA2 database. ( K ) The expression of KRT7 in patients with PDAC of different AJCC stages according to data from the GEPIA2 database.
Article Snippet: Furthermore, immunohistochemical (IHC) staining data for
Techniques: Over Expression, Expressing
Journal: Scientific Reports
Article Title: KRT7 promotes pancreatic cancer metastasis by remodeling the extracellular matrix niche through FGF2-fibroblast crosstalk
doi: 10.1038/s41598-024-84129-1
Figure Lengend Snippet: The expression and liver metastasis-promoting effect of KRT7 in PDAC. ( A ) The RNA level of KRT7 in PDAC tissue and normal tissue samples from our in-house cohort. ( B ) Representative UMAP plot and a corresponding plot showing the expression of KRT7 in different cell types according to data from the online PDAC scRNA-Seq CancerSCEM database. ( C ) Representative images of IHC staining for KRT7 in samples from the Huaman Protein Atlas database. ( D ) The RNA and protein levels of KRT7 after transfection of EV or a KRT7 overexpression vector into PANC1 cells. ( E ) The RNA and protein levels of KRT7 after transfection of EV or a KRT7 overexpression vector into ASPC1 cells. ( F ) Primary tumor weights and volumes in BALB/c nude orthotopic mice injected with PANC1 cells transfected with the EV or KRT7 overexpression vector. The mice were euthanized 6 weeks after injection; n = 8 mice per group. ( G ) Primary tumor weights and volumes in the BALB/c nude orthotopic mice injected with ASPC1 cells transfected with the EV or KRT7 overexpression vector. The mice were euthanized 6 weeks after injection; n = 8 mice per group. ( H ) Incidence of liver metastases in BALB/c nude orthotopic mice injected with PANC1 and ASPC1 cells transfected with the EV or KRT7 overexpression vector; n = 8 mice per group. The mice were euthanized at 4 weeks after injection. ( I ) Quantification of liver metastatic nodes in the BALB/c nude orthotopic mouse model. ( J ) Representative images of gross morphology of metastatic liver tumors in the BALB/c nude orthotopic mouse model. ( K–M ) Primary tumor weights, tumor volumes, incidence of liver metastases, number of liver metastasis nodes and representative gross morphology of metastatic liver tumors in C57BL/6 orthotopic mice injected with 10 6 PA02 cells transfected with the EV and KRT7 overexpression vector; n = 8 mice per group. The mice were euthanized 6 weeks after injection.
Article Snippet: Furthermore, immunohistochemical (IHC) staining data for
Techniques: Expressing, Immunohistochemistry, Transfection, Over Expression, Plasmid Preparation, Injection
Journal: Scientific Reports
Article Title: KRT7 promotes pancreatic cancer metastasis by remodeling the extracellular matrix niche through FGF2-fibroblast crosstalk
doi: 10.1038/s41598-024-84129-1
Figure Lengend Snippet: The impacts of KRT7 on PDAC proliferation and metastasis in vitro. ( A,B ) Growth in the 3D tumor spheroid formation assay. A growth curve was generated by normalizing the tumor volume to the initial volume; n = 3 biologically independent samples; scale bar: 50 μm. ( C ) Western blot analysis of PCNA levels in PDAC and ASPC1 cells. ( D ) CCK-8 assay. ( E,F ) Migration of tumor cells in the 3D tumor spheroid formation assay. The migration area is expressed relative to the initial tumor spheroid area during spheroid migration. The quantitative data are shown on the right; n = 3 biologically independent samples; scale bar = 50 μm.
Article Snippet: Furthermore, immunohistochemical (IHC) staining data for
Techniques: In Vitro, Tube Formation Assay, Generated, Western Blot, CCK-8 Assay, Migration
Journal: Scientific Reports
Article Title: KRT7 promotes pancreatic cancer metastasis by remodeling the extracellular matrix niche through FGF2-fibroblast crosstalk
doi: 10.1038/s41598-024-84129-1
Figure Lengend Snippet: KRT7 inhibits CAF infiltration and ECM deposition in PDAC. ( A ) Plot of KRT7 expression in PDAC cells and the percentage of immune cells in the corresponding sample according to data for 24 samples from the online PDAC scRNA-Seq CancerSCEM database. ( B ) Representative images and graph of α-SMA staining in KRT7 high and KRT7 low PDAC tissue samples from our in-house cohort (n = 20 each group); scale bar: 100 µm. ( C ) Representative picrosirius-stained images and a graph of picrosirius staining in KRT7 high and KRT7 low PDAC tissue samples from our in-house cohort (n = 20 each group); scale bar: 100 µm.
Article Snippet: Furthermore, immunohistochemical (IHC) staining data for
Techniques: Expressing, Staining
Journal: Scientific Reports
Article Title: KRT7 promotes pancreatic cancer metastasis by remodeling the extracellular matrix niche through FGF2-fibroblast crosstalk
doi: 10.1038/s41598-024-84129-1
Figure Lengend Snippet: KRT7 promotes metastasis-conducive ECM niche formation by inhibiting CAF infiltration through FGF2. ( A ) Western blot analysis of TGF-beta levels in PANC1 cells and analysis of TGF-beta levels in the corresponding culture medium by ELISA. ( B ) Western blot analysis of FGF2 levels in PANC-1 cells and analysis of TGF-beta levels in the corresponding culture medium by ELISA. ( C ) The RNA level of FGF2 in PANC1 and ASPC1 cells. ( D ) Analysis of FGF2 levels in primary tumor tissue homogenates from BALB/c nude orthotopic model mice by ELISA. ( E ) Correlation analysis between KRT7 RNA levels and FGF2 RNA levels according to data from the online ENCORI PDAC dataset. ( F,G ) Representative images of α-SMA staining and picrosirius staining of primary tumors from BALB/c nude orthotopic model mice that received different treatments (saline treatment or FGF2 inhibitor treatment (NSC12, 2.5 mg/kg, iv. 3×/week)); n = 8 mice per group. The mice were sacrificed 6 weeks after injection. ( H ) ECM assembly in an in vitro Transwell invasion assay; scale bar: 50 μm. ( I‒K ) Incidence of liver metastasis, number of liver metastasis nodes and tumor weight in BALB/c nude orthotopic tumor model mice that received different treatments (saline treatment or FGF2 inhibitor treatment (NSC12, 2.5 mg/kg, iv. 3×/week)); n = 8 mice per group. The mice were sacrificed 6 weeks after injection. ( L ) Body weights of BALB/c nude orthotopic tumor model mice that received different treatments (saline treatment or FGF2 inhibitor treatment (NSC12, 2.5 mg/kg, iv. 3×/week)).
Article Snippet: Furthermore, immunohistochemical (IHC) staining data for
Techniques: Western Blot, Enzyme-linked Immunosorbent Assay, Staining, Saline, Injection, In Vitro, Transwell Invasion Assay